Finding NASH patients for clinical trials can be a major challenge. Acurian has a best-in-class capability to help you find more NASH patients, faster. With a proprietary database of 120 million households, including thousands of confirmed NAFLD patients, plus state-of-the-art, noninvasive screening, we are able to deliver high quality patients who meet your stringent criteria, with fixed budget models.
The sponsor needed data from this study as quickly as possible in order to begin its phase III trial in patients with symptomatic GERD not completely responsive to proton pump inhibitors.
Opioid-induced constipation (OIC) is projected to hit $2.8 billion by 2022, according to Credence Research (March 2016 report). Growth for this market will come from the introduction of several new drugs, including this sponsor’s compound, which would be the first to market in a new class.
This small pharmaceutical company was in a race to be first to market for diarrhea-predominant Irritable Bowel Syndrome (IBS), a market with multi-billion dollar potential. An 11-month enrollment timeline was critical to the successful completion of a two-protocol, phase III program.
This mid-sized biopharmaceutical company’s growth strategy relies on the development of novel immunotherapy agents. One of its biologics carried the potential to treat a range of autoimmune diseases, including Crohn’s disease or CD. The sponsor believed this agent could fill a substantial, unmet need for CD patients: more effective maintenance therapies that are also safe for long-term use.
We make gastroenterology trials less painful…and easier to digest.
Our success is a combination of aligning the enrollment process with today’s realities, customized solutions, and true insight into site relationships. From OIC/OIBD, IBS and GERD, to Crohn’s disease, Acurian makes trials a lot less trying.
Acurian is the leader in the patient recruitment and retention industry.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.